Pazopanib

Catalog No.S3012 Synonyms: GW786034

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (a,b) Effect of Pazopanib on vascular network integrity. VMOs were exposed to drug from day 4 to 6. Data are normalized to day of first drug exposure and are shown as percentage of control. Error bars show mean ± s.d (n = 3) (p < 0.05 vs control).

    Sci Rep, 2016, 6:31589. Pazopanib purchased from Selleck.

    J Virol 2011 85(5), 2296-303. Pazopanib purchased from Selleck.

  • Three RCC cell lines treated with different concentrations of TKI and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib purchased from Selleck.

    (B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

    Transl Oncol, 2016, 9(3):197-202. Pazopanib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnLQTY5pcWKrdHnvckBw\iCqdX3hckBGd0xvMT3j[YxtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIHnjOVA:Oi56OXWtNFUh|ryP MX3TRW5ITVJ?
human AN3-CA cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXy0WJdDUW6qaXLpeIlwdiCxZjDoeY1idiCDTkOtR2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5yNTDuUS=> NFjWNXZUSU6JRWK=
human CGTH-W-1 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWnSTlN2UW6qaXLpeIlwdiCxZjDoeY1idiCFR2TIMXcuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRyLkCxJI5O NV\ndI8zW0GQR1XS
human GDM-1 cell M4C5[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlnuTY5pcWKrdHnvckBw\iCqdX3hckBITE1vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwN{46QSCwTR?= NWHOVpY{W0GQR1XS
human A204 cell NGXiOI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4\4XWlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwPU4xPiCwTR?= MVjTRW5ITVJ?
human G-402 cell MmHSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGcuPDB{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUOxMlg1KG6P M4OxWHNCVkeHUh?=
human MFE-296 cell M{ToUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG\GfIJKdmirYnn0bY9vKG:oIHj1cYFvKE2IRT2yPVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjV7MEKyJO69VQ>? NV3t[Wh4W0GQR1XS
human NOS-1 cell M13GO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn3aTY5pcWKrdHnvckBw\iCqdX3hckBPV1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBq[zVyPUCuOlU6QDdizszN M1fQdXNCVkeHUh?=
human KG-1 cell MlzaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXrJcohq[mm2aX;uJI9nKGi3bXHuJGtINTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkexO|U2KM7:TR?= MWfTRW5ITVJ?
human HT55 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXzBWY5RUW6qaXLpeIlwdiCxZjDoeY1idiCKVEW1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46QDd6MTFOwG0> NU\0NoZVW0GQR1XS
human MG-63 cell NWjFUlVwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXjGRVkzUW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODBzNE[g{txO MXPTRW5ITVJ?
human CCF-STTG1 cell MofWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGNETi2VVGTHNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F697zOIFnDOVA:OS5yNEm4NUDPxE1? M4f0WXNCVkeHUh?=
human RT-112 cell M13FSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXflcm96UW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjFyM{e2JO69VQ>? MW\TRW5ITVJ?
human MC-IXC cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXfJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVE2OTJizszN M3;pTnNCVkeHUh?=
human HUTU-80 cell NIrSWZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NILZSWhKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ6MUCzJO69VQ>? M1;5V3NCVkeHUh?=
human MV-4-11 cell NEXmNYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVrJcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM1PTBzIN88US=> MXHTRW5ITVJ?
human LCLC-103H cell MlfXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3\0RmlvcGmkaYTpc44hd2ZiaIXtZY4hVEOOQz2xNFNJKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[Xl? M{mwUXNCVkeHUh?=
human G-401 cell NIXjdFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4DidmlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ3PDJzIN88US=> MnL1V2FPT0WU
human A704 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4nKN2lvcGmkaYTpc44hd2ZiaIXtZY4hSTdyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlA{OjNizszN NGSybmVUSU6JRWK=
human ESS-1 cell NGC0PI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NETCRo5KdmirYnn0bY9vKG:oIHj1cYFvKEWVUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43ODN7NjFOwG0> NGPqT|lUSU6JRWK=
human HLE cell M{DZOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNkO4NFQh|ryP NWTYPZRFW0GQR1XS
human NY cell Mo[1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1zKe2lvcGmkaYTpc44hd2ZiaIXtZY4hVlliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLki0PFIyKM7:TR?= NULGWVNmW0GQR1XS
human A427 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnnRTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT65PFA4PSEQvF2= NH\oXYxUSU6JRWK=
human SK-N-DZ cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYXDc4xDUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWRbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yMkO4NUDPxE1? MkDUV2FPT0WU
human J82 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFjlTXRKdmirYnn0bY9vKG:oIHj1cYFvKEp6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNFYxQDhizszN MUXTRW5ITVJ?
human GI-1 cell M2\YNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVS1XndJUW6qaXLpeIlwdiCxZjDoeY1idiCJST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zOjl3MTFOwG0> M17mU3NCVkeHUh?=
human NCI-H716 cell NIrDeG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1yye2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3NVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjNzNkOzJO69VQ>? M{TaUHNCVkeHUh?=
human SF126 cell NUTMdZV{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYD0c|N4UW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDd2NUmg{txO NUTvTZdvW0GQR1XS
human H4 cell MmPtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVPJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53MUK2NkDPxE1? M2ewcHNCVkeHUh?=
human LB831-BLC cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIrvdJJKdmirYnn0bY9vKG:oIHj1cYFvKEyEOEOxMWJNSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUS1OlYh|ryP MYHTRW5ITVJ?
human HCC1395 cell NXjXNVh1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NY\OVZVCUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxN|k2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53OEG1OkDPxE1? M3LnNHNCVkeHUh?=
human LK-2 cell NYjneHc5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1jWTmlvcGmkaYTpc44hd2ZiaIXtZY4hVEtvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOlQ2PjlizszN MkLRV2FPT0WU
human G-361 cell M{DqPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NILJOppKdmirYnn0bY9vKG:oIHj1cYFvKEdvM{[xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xPDB6MjFOwG0> M2PqR3NCVkeHUh?=
human NCI-H2342 cell NV\BZXNxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkO0NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NiCLQ{WwQVMvOTN|MU[g{txO NWXNboM{W0GQR1XS
human SK-LU-1 cell  NXrsbIdyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIXPbJFKdmirYnn0bY9vKG:oIHj1cYFvKFONLVzVMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjF6N{[3JO69VQ>? NXy2RnY3W0GQR1XS
human IGROV-1 cell  M4Hv[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI1PzF|IN88US=> NYfMd5oxW0GQR1XS
human EB2 cell NX\Td2FGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWHJcohq[mm2aX;uJI9nKGi3bXHuJGVDOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwMkixOlgh|ryP Moe2V2FPT0WU
human CAL-54 cell NUTIO4pyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkHSTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI5OzZ5IN88US=> M3WxS3NCVkeHUh?=
human LB1047-RCC cell NWjZd4xNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlvkTY5pcWKrdHnvckBw\iCqdX3hckBQS1WELV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlM{OTN4ODFOwG0> M1rrRXNCVkeHUh?=
Daudi cell M3TRXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjV|MU[0JO69VQ>? NFTUbFBUSU6JRWK=
human Daudi cell M4XLO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2jLeGlvcGmkaYTpc44hd2ZiaIXtZY4hTGG3ZHmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlY3OjF7IN88US=> M3n0eHNCVkeHUh?=
human A172 cell M13TRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3PnSmlvcGmkaYTpc44hd2ZiaIXtZY4hSTF5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuO|M4QSEQvF2= M1vDOXNCVkeHUh?=
human KGN cell NE\aV5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3uxS2lvcGmkaYTpc44hd2ZiaIXtZY4hU0eQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6wOlcxQSEQvF2= NV3kRpZ5W0GQR1XS
human SNG-M cell NV70R4w3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmjTTY5pcWKrdHnvckBw\iCqdX3hckBUVkdvTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNFg3PjlizszN NV\STYRYW0GQR1XS
human SW1710 cell NYHIZmJKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlPrTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlQ4OzF6IN88US=> MoG5V2FPT0WU
human HT29 cells NF:4RpNRem:uaX\ldoF1cW:wIHHzd4F6 MmnqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVEK5JINmdGy|IHnuJJNmenWvIHPvcpRicW6rbnegcYVlcXWv NVW0XYhuOTh4MkCzPFI>
human A375P cells MoLhVJJwdGmoZYLheIlwdiCjc4PhfS=> M2XKcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OXAh[2WubIOgbY4he2W{dX2gZ49vfGGrbnnu[{Bu\WSrdX2= NWHoRXRIOTh4MkCzPFI>
human HN5 cells M4rMeHBzd2yrZnXyZZRqd25iYYPzZZk> M4PRZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSF61JINmdGy|IHnuJJNmenWvIHPvcpRicW6rbnegcYVlcXWv M3HaNFE5PjJyM{iy
HUVEC M{XSVWZ2dmO2aX;uJIF{e2G7 M1;LW|Eh|ryP MoHBOkBp M17nN2FvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidIXi[UBnd3KvYYTpc44h[XRiMD6xJJVOKGGodHXyJFYhcHK|IHL5JG1ifHKrZ3XsJIF{e2G7 NWO5dGlsOjRyM{[wOFI>
human Daoy cell M3jQZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHT0cm1KdmirYnn0bY9vKG:oIHj1cYFvKESjb4mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc4QTR7IN88US=> NHHNblhUSU6JRWK=
human DMS-273 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXTJcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk3OjB{IN88US=> NHvVTGZUSU6JRWK=
human KU812 cell NVrUc4hPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV\iUnNTUW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzd6MUKg{txO Mn\lV2FPT0WU
human NCI-H727 cell M3vGVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnXCTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEeyO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDB7MEGg{txO NF21UFVUSU6JRWK=
human P30-OHK cell NVPEW206T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXzJcohq[mm2aX;uJI9nKGi3bXHuJHA{OC2RSFugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ3QTRizszN M4G1fHNCVkeHUh?=
human MIA-PaCa-2 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXLJcohq[mm2aX;uJI9nKGi3bXHuJG1KSS2SYVPhMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjZyNE[2JO69VQ>? MUjTRW5ITVJ?
human TT cell NG\GdZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2fr[GlvcGmkaYTpc44hd2ZiaIXtZY4hXFRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lk[2NlQh|ryP NWjXOIh5W0GQR1XS
human DK-MG cell NHXnSHRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mni1TY5pcWKrdHnvckBw\iCqdX3hckBFUy2PRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|IxOjhizqzt NX;ZRXhsW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
Synonyms GW786034

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02300545 Recruiting Sarcoma, Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8, 2015 Phase 2
NCT00674024 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 7, 2008 Phase 1
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine May 31, 2013 Phase 1
NCT01462630 Recruiting Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma Fox Chase Cancer Center|National Cancer Institute (NCI) November 3, 2011 Phase 2
NCT01468922 Completed Sarcoma|Stomach Neoplasms|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 24, 2011 Phase 1
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID